By Deborah Mitchell on March 31, 2013 – 8:33am for eMaxHealth
Diabetes Care Current News
In just 3 months, the Food and Drug Administration (FDA) has granted approval to four type 2 diabetes drugs, including Invokana, which is the first in its class. Yet while adding new items to the expanding type 2 diabetes drugs arsenal has its positive side, it’s not good enough, and here’s why.
Do we need four new type 2 diabetes drugs?
It’s no secret that type 2 diabetes is a growing epidemic, and that an increasing number and percentage of children and adolescents are developing this disease that was once largely seen only in adults. For young people in particular, onset of type 2 diabetes at an early age places them at greater risk for a lifetime of health complications and a shorter life span.
The four new type 2 diabetes drugs that won FDA approval since January 2013, including the latest, Johnson & Johnson’s Invokana (canaglifozin), provide current and future type 2 diabetics with more pharmaceutical treatment options. Before looking at those four new options, let’s consider how much they are needed.